In preclinical models, it had been shown before that dual GLP-1/GCG as well as dual GLP-1/GIP agonists improve metabolic parameters and are capable of fighting obesity [97,98]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.